FG-4497 Treatment Reduces Aortic Plaque Area in LDL Receptor-Deficient Mice
The areas of calcified plaques in the full-length aortas and at the aortic origin were reduced by ≈50% in the FG-4497treated HFD-fed Ldlr −/− mice when compared with the vehicle-treated controls (Figure 2A and 2B) ; no difference being found between the groups in the amount of plaque collagen ( Figure 2C ). There was a trend for a reduced total area of foam macrophages in the FG-4497 mouse plaques, and this difference disappeared when expressed in proportion to the reduced total plaque area ( Figure 2D ). The area of the necrotic cores of the FG-4497 mouse plaques was <30% of that in the controls ( Figure 2E ). The plaque sizes in the whole aorta and at the aortic origin correlated positively with body weight, serum cholesterol level, and the number of WAT macrophage aggregates suggesting that their reductions in the FG-4497-treated mice were protective against atherosclerosis development ( Figure 3A-3F ).
FG-4497 Treatment Stabilized HIF-1α and HIF-2α and Altered the Expression of Glucose and Lipid Metabolism Genes in the WAT and Liver of LDL Receptor-Deficient Mice
FG-4497 administration stabilized HIF-1α and HIF-2α in the liver ( Figure IA in the online-only Data Supplement). The hepatic mRNA levels of Sterol regulatory element-binding protein (Srebp1c), its targets Acetyl-CoA carboxylase α (Accα), Fatty acid synthase (Fas), and Stearoyl-CoA desaturase-1 (Scd1) were reduced in the HFD-fed FG-4497-treated Ldlr −/− mice, whereas that of Insulin receptor substrate 2 (Irs2), a reported HIF-2α target, which downregulates Srebp1c, 10, 11 was increased ( Figure IB in the online-only Data Supplement). The hepatic expression level of the key gene regulating cholesterol synthesis 3-OH-3-methylglutaryl-CoA reductase (Hmgcoar) and that of 3-OH-3-methylglutaryl-CoA synthase (Hmgcoas) was decreased in the FG-4497-treated Ldlr −/− mice to 68% and 62% of the vehicle-treated ones (P=0.06 and 0.08, respectively), whereas the mRNA for lipoprotein lipase (Lpl) was increased to 206% (P=0.07; Figure  IB in the online-only Data Supplement). The hepatic level of the glucose-regulated Glut2 was reduced in the FG-4497treated Ldlr −/− mice, and the expression of genes for glycolytic enzymes, established HIF-1α targets, 12 was in general increased in the FG-4497-treated Ldlr −/− mice ( Figure IB in the online-only Data Supplement). The WAT of the HFD-fed FG-4497-treated Ldlr −/− mice showed induction of HIF target glucose transport and glycolytic genes and Pyruvate dehydrogenase kinase 1 (Pdk1) and reduction in the expression of the inflammation marker Chemochine (C-C motif) ligand 2 (Ccl2) ( Figure IC in the online-only Data Supplement), the level of CCL2 being also lower in pooled sera of the FG-4497-treated Ldlr −/− mice than in the vehicle-treated ones (2.44 versus 2.91 pg/mL). The WAT Ccl2 mRNA levels correlated positively with the WAT macrophage aggregate number and the area 
Pharmacological HIF-P4H Inhibition Reduced Hepatic Cholesterol Synthesis and Increased Levels of Circulating Atherosclerosis-Protecting Autoantibodies in LDL Receptor-Deficient Mice
The levels of cholesterol, its precursors squalene, lanosterol, cholestenol, lathosterol, and desmosterol and the plant sterols, campesterol and sitosterol, which reflect cholesterol absorption efficiency, were determined in the liver and serum of the HFD-fed FG-4497 or vehicle-treated Ldlr −/− mice after 13 weeks. In agreement with the data in Figure 1H , the serum cholesterol level was reduced in the FG-4497-treated mice, but no decrease was seen in the liver total cholesterol level ( Table II in the online-only Data Supplement). The level of squalene, the first measurable intermediate of cholesterol biosynthesis after acetyl-CoA, was reduced both in the liver and serum of the FG-4497-treated animals, and its hepatic levels correlated positively with serum insulin levels (r=0.578; P=0.038), whereas the level of the anti-inflammatory desmosterol 13 and the plant sterol campesterol was increased in the liver but not in the serum (Table II in the online-only Data  Supplement) . Natural autoantibodies to oxidized lipids are reported to be protective against atherosclerosis development. [14] [15] [16] [17] Lipid oxidation leads to proinflammatory products, such as malondialdehyde-acetaldehyde (MAA). Oxidation-specific epitopes for natural autoantibodies are generated in the LDL that accumulates in vascular walls. 16 Because the FG-4497treated Ldlr −/− mice had less WAT inflammation and were protected against atherosclerosis, we studied autoantibody binding to copper-oxidized LDL (CuOx-LDL) and MAAmodified LDL (MAA-LDL) in their sera. Total IgG and IgM levels and the oxidation-specific autoantibody levels increased similarly in the sera of the FG-4497-treated and vehicle-treated groups during HFD feeding ( Figure 4A -4F). The only significant difference between the 2 groups was the continuous increase in CuOx-LDL IgG autoantibodies in the FG-4497-treated mice, whereas their levels in the vehicletreated mice declined after an initial increase at 9 weeks ( Figure 4B ). A significant negative correlation was found between the difference in the increase in CuOx-LDL IgG autoantibodies and plaque size at the aortic origin but not in the whole aorta ( Figure 5G and 5H).
Genetic HIF-P4H-2 Inhibition Protects From Atherosclerosis
FG-4497 inhibits all 3 HIF-P4Hs with similar IC 50 values. 4 To study whether the atherosclerosis-protective phenotype was specifically caused by HIF-P4H-2 inhibition, we crossed our Hif-p4h-2 gt/gt mice with Ldlr −/− mice, but obtained no live Hif-p4h-2 gt/gt /Ldlr −/− pups, their death occurring at E9.5 (data not shown). We therefore crossed the Hif-p4h-2 gt/gt mice with the Ldlr Hlb301 mice, which have a missense mutation C699Y in LDL receptor, 18 and obtained live double gene-modified pups.
The Ldlr Hlb301 mice were generated with chemical ethylnitrosourea mutagenesis, and their genome has not been fully characterized for potential additional mutations. 18 These Ldlr Hlb301 / Hif-p4h-2 gt/gt mice had similar, but not identical, reductions in their tissue Hif-p4h-2 mRNA levels to those of the parental Hif-p4h-2 gt/gt mice ( Figure IIA in the online-only Data Supplement). Similar to the parental line, HIF-1α, but not HIF-2α, was stabilized in WAT of the Ldlr Hlb301 /Hif-p4h-2 gt/gt mice, whereas in liver, opposite to the Hif-p4h-2 gt/gt mice, HIF-1α but not HIF-2α was stabilized ( Figure IIB in the online-only Data Supplement). 9 There were no differences in the hepatic mRNA levels of Srebp1c, Accα, Fas, Scd1, and Irs2 between the Ldlr Hlb301 /Hif-p4h-2 gt/gt and the Ldlr Hlb301 mice ( Figure  IIC in the online-only Data Supplement). The Ldlr Hlb301 /Hif-p4h-2 gt/gt mice were lighter than the Ldlr Hlb301 mice when fed normal chow, but this difference disappeared when fed HFD ( Figure 5A ). There was also no difference between the genotypes in WAT weight or adipocyte size, but the numbers of WAT macrophage aggregates were lower in the double gene-modified mice ( Figure 5B and 5C). No difference was either seen in the homeostasis model assessment-insulin resistance scores ( Figure IID in the online-only Data Supplement). Surprisingly, the Ldlr Hlb301 /Hif-p4h-2 gt/gt mice, unlike the Hif-p4h-2 gt/gt mice, 9 did not have reduced serum cholesterol levels either on normal chow or on HFD ( Figure 5D ). The Ldlr Hlb301 /Hif-p4h-2 gt/gt mice were nevertheless protected against atherosclerosis development, as shown by the ≈50% reduction in the area of plaque over the total aortic area and the ≈40% reduction at the aortic origin ( Figure 5E and 5F ). The area of foam macrophages was >60% smaller in the plaques of the Ldlr Hlb301 /Hif-p4h-2 gt/gt than that of the Ldlr Hlb301 mice ( Figure 5G ), and the area of the necrotic core was likewise reduced by >60% ( Figure 5H ), whereas no difference was seen in the amount of plaque collagen ( Figure IIE in the online-only Data Supplement). The number of WAT macrophage aggregates correlated positively with plaque sizes in the whole aorta and at the aortic origin, suggesting that also in this model reduced WAT inflammation associated with atherosclerosis protection ( Figure 5I ). There was a trend for increases in the levels of serum IgM autoantibodies to CuOx-LDL and MAA-LDL before exposure to HFD in the Ldlr Hlb301 /Hif-p4h-2 gt/gt mice relative to the Ldlr Hlb301 mice; these increases being statistically significant since 9 weeks on HFD ( Figure 6A ). There was also a significant increase in serum IgG autoantibodies to CuOx-LDL and MAA-LDL at 9 weeks in the Ldlr Hlb301 /Hif-p4h-2 gt/gt mice ( Figure 6B ). The amount of IgM CuOx-LDL and IgM MAA-LDL autoantibodies correlated negatively with plaque necrotic core area (r=−0.452; P=0.016 and r=−0.542; P=0.003, respectively), and the former with plaque size at the aortic origin ( Figure 6C ). Our data suggest that the modulation of adipose tissue inflammation and innate immunity rather than changes in lipid metabolism may have played an important role in the protection against atherosclerosis in the Ldlr Hlb301 /Hif-p4h-2 gt/gt mice.
HIF-P4H-2 Hypomorphic Mice Have Increased Levels of Circulating Atherosclerosis-Protecting Autoantibodies and Reduced Hepatic Cholesterol Synthesis
To study, whether the increased atherosclerosis-protecting autoantibody levels in the Ldlr Hlb301 /Hif-p4h-2 gt/gt mice were because of HIF-P4H-2 deficiency or some noncharacterized mutation in the Ldlr Hlb301 mice, we determined autoantibody binding to modified LDL in the sera of the Hif-p4h-2 gt/gt mice. The levels of CuOx-LDL and MAA-LDL IgG and IgM autoantibodies were higher in the Hif-p4h-2 gt/gt than in the wildtype mice, whereas there was no difference in IgA levels ( Figure 6D ). We also determined the levels of cholesterol and its precursors in the Hif-p4h-2 gt/gt mice. There was no difference in total hepatic cholesterol levels between the Hif-p4h-2 gt/gt and the wild-type mice, but the level of squalene was significantly reduced in the Hif-p4h-2 gt/gt livers, as in FG-4497-treated mice, supporting reduced synthesis ( Table III in the onlineonly Data Supplement). The hepatic desmosterol level was increased in the Hif-p4h-2 gt/gt mice agreeing with data with the pharmacological inhibitor (Table III in Figure 1H ; Table  II in the online-only Data Supplement). The 30% reduction in the serum squalene level in the Hif-p4h-2 gt/gt mice was not statistically significant, but the serum level of the next measurable cholesterol synthesis intermediate, lanosterol, was significantly reduced ( Table III in 
the online-only Data Supplement).
Having previously found that the hepatic mRNA levels for Srebp1c, Accα, and Fas were lower and that for Irs2 higher in the Hif-p4h-2 gt/gt mice than in the wild-type littermates, 9 we now observed a significant reduction in the hepatic Scd1 mRNA, while the reduction to 85% in Hmgcr and the induction of Lpl to 181% did not reach significance ( Figure 6E) ; however, all these changes being similar to those seen here for the HFD-fed FG-4497-treated Ldlr −/− mice ( Figure IB in the and Ldlr Hlb301 /Hif-p4h-2 gt/gt mice at 0, 9, and 13 wk on HFD. B, Serum total IgG, IgG bound to CuOx-LDL, and IgG bound to MAA-LDL at 0, 9, and 13 wk. C, Correlation between the level of CuOx-LDL IgM at 13 wk and the area of plaques in a cross section of the aortic origin. n=14 per group. D, Natural autoantibodies in the serum of male Hif-p4h-2 gt/gt (gt/gt) and wild-type mice (wt) at the age of 3 to 7 mo (n=7-8 per group). E, Quantitative polymerase chain reaction (qPCR) analyses of the mRNA levels of lipid metabolism genes in the liver of Hif-p4h-2 gt/gt mice when compared with the wt (n=7-8 per group). The expression of each gene was studied relative to β-actin. F, qPCR analyses of the mRNA levels of Hif1a and Hif2a and lipid and glucose metabolism genes in the primary Hif-p4h-2 gt/gt hepatocytes followed by Hif1a or Hif2a siRNA transfection relative to control siRNA transfection (n=4 per group). Abca1 indicates ATP-binding cassette subfamily A member 1; Accα, acetyl-CoA carboxylase α; ApoB, apolipoprotein B; Fas, fatty acid synthase; Scd1, stearoyl-CoA desaturase 1; Hmgcr and Hmgcs, HMG-CoA reductase and synthase; Insig1 and Insig2, insulin-induced gene 1 and 2; Ldlr, low density lipoprotein receptor; Lpl, lipoprotein lipase; Irs2, insulin receptor substrate 2; Pdk1, pyruvate dehydrogenase kinase 1; Pfkl, phosphofructokinase; and Srebp1c, sterol regulatory element-binding protein 1c.
online-only Data Supplement). The Hif-p4h-2 gt/gt mice, unlike the FG-4497-treated Ldlr −/− mice, show stabilization of only HIF-2α in their livers and no induction in the glycolytic HIF-1α targets. 9 To establish a causality between HIFα stabilization and the observed phenotype, we extracted primary hepatocytes from the Hif-p4h-2 gt/gt mice and knocked down Hif1α or Hif2α by siRNA transfections in them. Two independent siRNAs for Hif1α and Hif2α resulted in >85% and 60% to 70% downregulation of the corresponding mRNA levels, respectively, and interestingly, downregulation of one isoform resulted in upregulation of the other ( Figure 6F ). The downregulation of either Hif1α or Hif2α resulted in downregulation of Irs2 and upregulation of Srebp1c, Accα, Fas, and Scd1mRNA levels. Downregulation of Hif1α in these Hif-p4h-2 gt/gt hepatocytes devoid of HIF-1α stabilization did not alter the mRNA levels of the glycolytic genes Pfkl and Pdk1, as expected, whereas downregulation of Hif2α increased their levels, most likely because of simultaneous Hif1α mRNA upregulation ( Figure 6F ). The mRNA for Hmgcr was upregulated when either Hif1α or Hif2α was downregulated indicating that it is regulated by both HIFαs.
Discussion
Hypercholesterolemia and dyslipidemia are regarded as the key risk factors for the development of atherosclerosis, and therefore the treatments concentrate on lowering the elevated cholesterol levels in risk subjects. HIF has been suggested to have both detrimental and beneficial roles in atherosclerosis. 6, 7 Most human studies show that increased HIF-1α expression correlates with more advanced atherosclerotic plaques. 19 On the other hand, overexpression of HIF-1α in mouse lymphocytes attenuated inflammation and reduced aortic lesions. 6 Epidemic studies point to an association between altitudeinduced hypoxia and protection against ischemic heart disease and suggest that HIF stabilization may be involved in this protection. 20 HIF-P4H-2 inhibition leads to improved lipid and glucose metabolism, reduced serum cholesterol levels, and protection from obesity and metabolic dysfunction. 9, 21, 22 We present evidence here that pharmacological and genetic HIF-P4H-2 inhibition also protects from atherosclerosis development.
Cholesterol levels are regulated in multiple ways. We show here that HIF-P4H-2 inhibition driven HIF-1α and HIF-2α stabilization resulted in reduced serum cholesterol levels via several mechanisms ( Figure III in the online-only Data Supplement). First, HIF-P4H-2 inhibition reduced insulin resistance and its levels in serum. Because insulin increases the activity of 3-OH-3-methylglutaryl-CoA reductase, the lower insulin levels after HIF-P4H-2 inhibition likely reduced its catalytic activity, which accounted for the lower squalene levels detected in the livers of the FG-4497-treated Ldlr −/− and Hif-p4h-2 gt/gt mice and in the serum of the former, and the reduced cholesterol synthesis in liver. Second, the hepatic HIF-2α stabilization in the FG-4497-treated Ldlr −/− and Hif-p4h-2 gt/gt mice increased the mRNA levels of the target gene Irs2, 10 which is known to downregulate Srebp1c by competing with binding of the FOXO transcription factor to the Irs2 promoter insulin-responsive elements. 23 It has also been reported that Srebp1c is a direct target of insulin, and therefore the lower insulin levels after HIF-P4H-2 inhibition may have contributed to the lower Srebp1c mRNA levels also independently from Irs2 increase. 24 Moreover, it has been shown that both HIF-1α and HIF-2α can directly downregulate Srebp1c, 11 which agrees with our data from the primary hepatocytes. SREBPs are key transcriptional regulators of hepatic lipid synthesis, SREBP1c being primarily, but not exclusively, responsible for fatty acid and SREBP2 for cholesterol synthesis. 25 Therefore, the reduced mRNA levels of hepatic Hmgcr in the FG-4497-treated Ldlr −/− and to a smaller extent in the Hif-p4h-2 gt/gt mice were likely because of their reduced Srebp1c levels because no reduction in Srebp2 mRNA was detected. Furthermore, the hepatic expression levels of the Srebp1c downstream targets Fas, Accα, and Scd1 were reduced in the FG-4497-treated Ldlr −/− and Hif-p4h-2 gt/gt mice probably accounting for decreased fatty acid synthesis and de novo lipogenesis, as found earlier in the Hif-p4h-2 gt/gt liver, 9 and explaining the reduced liver weights seen here. Third, the overall improved glucose tolerance after global HIF-P4H-2 inhibition, which manifested in the FG-4497-treated Ldlr −/− mice as a reduction in the glucose-regulated hepatic Glut2 mRNA level, likely reduced glucose uptake by the liver and diminished the levels of acetyl-CoA, the building block for cholesterol synthesis, as reported earlier for the Hif-p4h-2 gt/gt mice. 9 The observed increased hepatic Lpl mRNA levels in the FG-4497-treated Ldlr −/− and the Hif-p4h-2 gt/gt mice, and the increased levels of campesterol in the former, were most likely methods to compensate for the reduced endogenous cholesterol synthesis in liver. In summary, these findings suggest that hepatic HIF-2α stabilization and reduced insulin resistance, seen in the FG-4497-treated Ldlr −/− and Hif-p4h-2 gt/gt mice, but not in the Ldlr Hlb301 /Hif-p4h-2 gt/gt mice, were responsible for the lower serum cholesterol levels.
Atherosclerosis is not only because of high cholesterol levels. Immunology plays a central role in its development and progression and increased titers of autoantibodies to Ox-LDL are associated with atherosclerosis protection. 15, 16, 26 These autoantibodies, part of innate immunity and mainly secreted by the B-1 cells, recognize the inflammationinduced modified LDL particles and can prevent the excessive accumulation of cell debris and modified LDL in the artery wall. 16, 26 The Ldlr Hlb301 /Hif-p4h-2 gt/gt mice, which had reduced numbers of WAT macrophage aggregates and increased autoantibody levels against CuOx-LDL and MAA-LDL, but no reduced serum cholesterol levels, were also protected against the development of atherosclerosis. The FG-4497treated Ldlr −/− mice also had higher levels of autoantibodies against CuOx-LDL at 13 weeks than did the vehicle-treated Ldlr −/− mice and reduced numbers of WAT macrophage aggregates. The increased levels of autoantibodies correlated negatively with plaque size at the aortic origin, and the reduced WAT macrophages correlated positively with plaque size both in the whole aorta and at the aortic origin, suggesting that changes in innate immunity and WAT inflammation may have played a role in the protection of these mice from atherosclerosis development ( Figure III in the online-only Data Supplement). The plaques at the aortic origins of the FG-4497-treated HFD-fed Ldlr −/− and Ldlr Hlb301 /Hif-p4h-2 gt/ gt mice had smaller necrotic cores, which can have at least partially accounted for their increased autoantibody levels. Importantly, the increased levels of autoantibodies were also seen in the Hif-p4h-2 gt/gt mice verifying their specificity for the HIF-P4H-2 inhibition and bringing up the possibility of therapeutic use of HIF-P4H-2 inhibition to increase autoantibodies for host homeostasis mediation for the treatment of other chronic inflammatory diseases in addition to atherosclerosis.
HIFs become stabilized during inflammatory processes, and hypoxia and inflammation are intimately linked. 27 Genetic and pharmacological HIF-P4H inhibition and the following HIF stabilization have been associated with protection from some inflammatory conditions, such as the inflammatory bowel disease including ulcerative colitis and Crohn disease. 27, 28 The protection against colitis included HIF-1-mediated induction of FoxP3 and increase in abundance and function of regulatory T cell (Tregs). 29 Because Tregs, and the suppressive cytokines produced by them, have been implicated in atherosclerosis protection, pharmacological HIF-P4H-2 inhibition may further diminish vascular inflammation by inducing them. 30 More recently, HIF-1α-driven optimization of carbohydrate metabolism, also acquired with a nonspecific 2-oxoglutarate inhibitor analogue DMOG, during an inflammatory acute lung injury, provided lung protection and dampened inflammation. 31 The data available suggest that HIFα stabilization via HIF-P4H inhibition can modulate immunologic responses, making them potential therapeutic targets in the treatment of chronic inflammatory diseases. Our data provide evidence for the pharmacological use of HIF-P4H-2 inhibition for the prevention of atherosclerosis development, such therapy combining reductions in serum cholesterol levels with modulation of innate immunity and protection against inflammation.
